onr:"swepub:oai:lup.lub.lu.se:a9c506f2-952a-4363-b418-6712bdd373a8"
Search: onr:"swepub:oai:lup.lub.lu.se:a9c506f2-952a-4363-b418-6712bdd373a8" > Follow-up of pituit...
- 1 of 1
- Previous record
- Next record
- To hitlist
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials
- Jimenez, Camilo (author)
-
- Burman, Pia (author)
- Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups
- Abs, Roger (author)
- show more...
- Clemmons, David R. (author)
- Drake, William N. (author)
- Hutson, Kent R. (author)
- Messig, Michael (author)
- Thorner, Michael O. (author)
- Trainer, Peter I. (author)
- Gagel, Robert F. (author)
- show less...
- (creator_code:org_t)
- 2008
- 2008
- English.
- In: European Journal of Endocrinology. - 1479-683X. ; 159:5, s. 517-523
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Objective: We examined pituitary tumor volumes in patients treated with pegvisomant for 18 months or longer and in whom the tumors were monitored for at least 3 years. We present details on 9 of 304 patients in clinical trials with pegvisomant who experienced tumor growth within the first year of treatment. Method: Magnetic reonance images prior to start of pegvisomant and at last follow-up were examined in 43 patients (14% of participating patients). Twenty-nine had received prior radiation therapy (18% of irradiated patients and all but live received somatostatin analogs between periods of pegvisomant treatment. Results: At follow-up, the received tumor volume was 0.6 cc (range 0.0-19.7 ccl. in comparison with 1.6 cc (0.0-19.7 cc) at baseline (P<0.001). Twenty-five patients, of which 23 received radiation therapy, had tumor volume reduction therapy, had an increase in tumor volume from 1.61 to 1.93 cc. Of the nine patients with tumor growth, six had progressive growth before initiating pegvisomant. Two patients with stable tumors while on octreotide experienced enlargement after octreotide discontinuation but remained stable on long-term pegvisomant therapy. Conclusion: The present data indicate that pegvisomant does not promote tumor growth and suggest that the nine observed cases of tumor progression. which occured within 8 months after commencing pegvisomant, are likely rebound expansions after discontinuation of somatostatin analogs and/or the natural history of aggressively growing pituitary tumors. Continued long-term surveillance of tumor volume, particularly in non-irradiated patients is recommended.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
- European Journal of Endocrinology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Jimenez, Camilo
- Burman, Pia
- Abs, Roger
- Clemmons, David ...
- Drake, William N ...
- Hutson, Kent R.
- show more...
- Messig, Michael
- Thorner, Michael ...
- Trainer, Peter I ...
- Gagel, Robert F.
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Endocrinology an ...
- Articles in the publication
- European Journal ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
